Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleENDOCRINE AND REPRODUCTIVE

A Mibefradil Metabolite Is a Potent Intracellular Blocker of L-Type Ca2+ Currents in Pancreatic β-Cells

Songwei Wu, Min Zhang, Pamela A. Vest, Arin Bhattacharjee, Li Liu and Ming Li
Journal of Pharmacology and Experimental Therapeutics March 2000, 292 (3) 939-943;
Songwei Wu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Min Zhang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pamela A. Vest
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arin Bhattacharjee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Li Liu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ming Li
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

It has been shown that mibefradil (Ro 40-5967) exerts a selective inhibitory effect on T-type Ca2+ currents, although at higher concentrations it can antagonize high voltage-activated Ca2+ currents. The action of mibefradil on Ca2+channels is use- and steady-state-dependent and the binding site of mibefradil on L-type Ca2+ channels is different from that of dihydropyridines. By using conventional whole-cell and perforated patch-clamp techniques, we showed that mibefradil has an inhibitory effect on both T- and L-type Ca2+currents in insulin-secreting cells. However, the effect on L-type Ca2+ currents was time-dependent and poorly reversible in perforated patch-clamp experiments. By using mass spectrometry, we demonstrated that mibefradil accumulates inside cells, and furthermore, a metabolite of mibefradil was detected. Intracellular application of this metabolite selectively blocked the L-type Ca2+ current, whereas mibefradil exerted no effect. This study demonstrates that mibefradil permeates into cells and is hydrolyzed to a metabolite that blocks L-type Ca2+ channels specifically by acting at the inner side of the channel.

Footnotes

  • Send reprint requests to: Ming Li, Ph.D., Department of Pharmacology, University of South Alabama, College of Medicine, Mobile, AL 36688. E-mail: mli{at}jaguar1.usouthal.edu

  • 1 This work was supported by National Institutes of Health Grant DK50151 and Juvenile Diabetes Foundation International Grant no. 197037.

  • Abbreviations:
    dm-mibefradil
    (1S,2S)-2-[2-[[3-(2-benzimidazolyl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-napthyl hydroxy hydrochloride
    • Received July 28, 1999.
    • Accepted October 25, 1999.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 292 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 292, Issue 3
1 Mar 2000
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
A Mibefradil Metabolite Is a Potent Intracellular Blocker of L-Type Ca2+ Currents in Pancreatic β-Cells
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleENDOCRINE AND REPRODUCTIVE

A Mibefradil Metabolite Is a Potent Intracellular Blocker of L-Type Ca2+ Currents in Pancreatic β-Cells

Songwei Wu, Min Zhang, Pamela A. Vest, Arin Bhattacharjee, Li Liu and Ming Li
Journal of Pharmacology and Experimental Therapeutics March 1, 2000, 292 (3) 939-943;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleENDOCRINE AND REPRODUCTIVE

A Mibefradil Metabolite Is a Potent Intracellular Blocker of L-Type Ca2+ Currents in Pancreatic β-Cells

Songwei Wu, Min Zhang, Pamela A. Vest, Arin Bhattacharjee, Li Liu and Ming Li
Journal of Pharmacology and Experimental Therapeutics March 1, 2000, 292 (3) 939-943;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Role of Protein Kinase C-Ras-MAPK p44/42 in Ethanol and Transforming Growth Factor-β3-Induced Basic Fibroblast Growth Factor Release from Folliculostellate Cells
  • Therapeutic Actions of an Insulin Receptor Activator and a Novel Peroxisome Proliferator-Activated Receptor γ Agonist in the Spontaneously Hypertensive Obese Rat Model of Metabolic Syndrome X
  • Hepatic Glucocorticoid Receptor Antagonism Is Sufficient to Reduce Elevated Hepatic Glucose Output and Improve Glucose Control in Animal Models of Type 2 Diabetes
Show more ENDOCRINE AND REPRODUCTIVE

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics